CytomX Therapeutics (CTMX) Return on Capital Employed (2015 - 2026)

CytomX Therapeutics has reported Return on Capital Employed for 12 years, with the latest figure at 20.72% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 8135.0% year-over-year to 20.72%; the trailing twelve-month figure through Mar 2026 stood at 20.72% (down 8135.0% YoY), and the FY2025 full-year result was 4.02%, down 3718.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 20.72%, down from 3.32% in the prior quarter.
• The five-year high for Return on Capital Employed was 60.62% in Q1 2025, with the low at 111.25% in Q4 2022.
• Historically, Return on Capital Employed has averaged 17.18% across 5 years, with a median of 11.67% in 2023.
• Annual changes were most pronounced in 2024 — Return on Capital Employed jumped 9987 bps — and 2026, when it plunged 8135 bps.
• CytomX Therapeutics' Return on Capital Employed stood at 111.25% in 2022, then soared by 90 bps to 11.67% in 2023, then soared by 587 bps to 56.83% in 2024, then sank by 106 bps to 3.32% in 2025, then slumped by 524 bps to 20.72% in 2026.
• The last three Return on Capital Employed figures came in at 20.72% (Q1 2026), 3.32% (Q4 2025), and 18.5% (Q3 2025), per Business Quant data.